Archives
-
Alosetron and Intestinal Stem Cell Research
2026-10-06
Alosetron is a selective 5-HT3 receptor antagonist associated with gastrointestinal motility modulation and visceral pain signaling research. A separate Cell Reports study established that CDC42-dependent epithelial polarity regulates intestinal stem cell and transit-amplifying cell balance through a YAP/TAZ–epiregulin–mTOR axis. This overview compares those evidence streams, explains possible conceptual links, and emphasizes that the published CDC42 study did not test alosetron or 5-HT3 receptor signaling. Any connection between alosetron and intestinal stem cell polarity therefore remains a hypothesis rather than an established finding.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-10-06
The 2026 FASEB Journal study evaluates chemically modified p21 mRNA delivered in lipid nanoparticles as a localized tumor suppressor replacement strategy for bladder cancer. Its preclinical evidence links bladder-localized expression with cell-cycle suppression, DNA-damage signaling, apoptosis, and reduced tumor growth, while also highlighting the limits of translating mouse-model findings into clinical treatment.
-
Tunicamycin, ER Stress, and Inflammation Research
2026-10-05
A source-grounded overview of Tunicamycin as a N-glycosylation inhibitor and endoplasmic reticulum stress inducer, with emphasis on macrophage-related claims, endothelial inflammation, ATF6 signaling, evidence strength, and translational limitations.
-
Z-WEHD-FMK as a Lens on Pyroptosis
2026-10-05
Z-WEHD-FMK can help researchers interpret inflammatory caspase dependence without treating pharmacological rescue as proof of a single molecular target. This article connects the inhibitor’s reported profile with the HOXC8–caspase-1 findings in lung cancer and defines the evidence boundaries for inflammation research, apoptosis assay design, and infectious disease research.
-
OMV-Displayed mRNA Antigens for Tumor Vaccines
2026-10-04
The reference study presents engineered bacteria-derived outer membrane vesicles as a surface-display platform for rapid mRNA antigen delivery. By combining L7Ae-mediated RNA capture with listeriolysin O-associated endosomal escape, the authors report antitumor activity, complete regression in a subset of mice, and protection against later tumor challenge, while emphasizing that the evidence remains preclinical.
-
RNA-Responsive Pyroptosis: Evidence and Limits
2026-10-03
A source-grounded overview of DAMAGE, a type III-E CRISPR nuclease-protease system reported to connect target RNA recognition with gasdermin-mediated pyroptosis. The article examines the study’s conceptual design, reported findings, possible research applications, evidence strength, assay context, and important limitations without presenting experimental procedures.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-10-02
The reference study develops chemically modified p21 mRNA packaged in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its preclinical data connect restored nuclear p21 expression with cell-cycle inhibition, DNA-damage signaling, apoptosis, bladder-localized protein expression, and reduced tumor growth.
-
Arachidonic Acid: Assays, Workflows & Troubleshooting
2026-10-01
Build better lipid-signaling experiments with Arachidonic Acid, from controlled eicosanoid biosynthesis assays to immune-response workflows. This guide connects practical formulation and sampling choices with emerging evidence that arachidonate metabolism can accelerate vaccine-induced humoral immunity.
-
TRPV1 Somatosensory Nerves Suppress Inflammation
2026-10-01
The 2025 iScience study shows that activating TRPV1-positive peripheral afferents at the nape engages a somato-autonomic reflex that limits systemic inflammation. Its combination of neural-circuit mapping, cytokine analysis, genetic validation, hormone measurements, and splenic RNA sequencing connects sensory stimulation with coordinated vagal, sympathetic, and immune regulation.
-
SR-202: PPARγ Mechanism Studies
2026-09-30
SR-202 enables loss-of-function testing of PPARγ in adipocyte differentiation, macrophage polarization, and metabolic inflammation. This workflow pairs selective antagonism with pathway-resolved controls, helping distinguish PPARγ-dependent biology from nonspecific changes in viability or transcription.
-
Mitochondrial Permeability Transition Pore Assay Kit Guide
2026-09-30
Learn how to use a Calcein AM fluorescent probe workflow to measure mitochondrial pore opening in live cells. This guide connects MPTP detection with patient-derived carpal tunnel models, cell death mechanism research, orthogonal validation, and practical troubleshooting.
-
Pemetrexed Workflows for Tumor Cell Research
2026-09-29
Pemetrexed disodium gives cancer chemotherapy research a practical way to connect folate-dependent nucleotide stress with apoptosis, senescence, and DNA-repair phenotypes. This workflow shows how to build reproducible dose-response assays and extend them into non-small cell lung carcinoma research and malignant mesothelioma models.
-
SM-102: Practical LNP Workflow for mRNA
2026-09-29
Build more reproducible lipid nanoparticle experiments with SM-102, from ethanol handling and rapid mixing to reporter-based release testing. The workflow also shows how to compare conventional LNP delivery with the monocyte-trafficked, lymph-node strategy reported in recent cancer-vaccine research.
-
CTP Solution in Translational mRNA Workflows
2026-09-28
A mechanistic and translational perspective on how CTP quality, handling, and assay control support p21 mRNA–LNP research, while clarifying the boundary between an upstream nucleotide reagent and therapeutic performance.
-
Palonosetron in CINV and RINV: 2013 Review
2026-09-28
Fabi and Malaguti review palonosetron’s pharmacology and clinical evidence for preventing nausea and vomiting related to radio- and chemotherapy, highlighting its long action and particular value in delayed CINV after moderately emetogenic chemotherapy. Their synthesis also identifies evidence gaps, including multi-day chemotherapy, and places the findings in the context of antiemetic combinations and clinical guidance available in 2013.